Literature DB >> 34127791

The Test of Infant Motor Performance (TIMP) in very low birth weight infants and outcome at two years of age.

Anitha Madayi1, Luming Shi2,3, Yanan Zhu2, Lourdes Mary Daniel4, Asila Alia Noordin5, Shelly Anne Marie Sherwood5, Victor Samuel Rajadurai6, Poh Choo Khoo6, Bin Huey Quek6, Pratibha Keshav Agarwal1.   

Abstract

OBJECTIVE: To evaluate TIMP in preterm very low birth weight (VLBW) infants, analyze risk factors, for atypical TIMP (aTIMP) scores, and explore TIMP's predictive relationship with Bayley-III at 2 years.
METHOD: A prospective study of 288 VLBW infants, with TIMP assessment between 34 weeks postmenstrual age and 16 weeks age, corrected for prematurity. RESULT: aTIMP scores were observed in 58/288(20%) infants, whose mean birth weight (BW) and gestational age were 1122 ± 257 g and 29.2 ± 2.12 weeks respectively. Risk factors included BW < 750 g (OR 4.8, 95% CI 1.3-17.7) and 750-1000 g (OR 2.9, 95% CI 1.2-6.9), presence of necrotizing enterocolitis ≥ stage 2; or focal intestinal perforation (OR 4.6, 95% CI 1.4-14.4), periventricular leukomalacia (OR 22.4,95% CI 2.0-246.2), and need for intensive resuscitation at birth (OR 2.7, 95% CI 1.3-5.5). aTIMP scores correlated with Bayley-III Score <85 in motor and cognitive domains with high specificity (80-82%) and negative predictive value (85-94%).
CONCLUSION: Identification of the risk factors for aTIMP scores will enable targeted intervention to optimize resources and outcomes in VLBW infants.

Entities:  

Year:  2021        PMID: 34127791     DOI: 10.1038/s41372-021-01067-w

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  1 in total

1.  Concurrent validity of the Alberta Infant Motor Scale to detect delayed gross motor development in preterm infants: A comparative study with the Bayley III.

Authors:  Plínio Luna de Albuquerque; Miriam Queiroz de Farias Guerra; Marília de Carvalho Lima; Sophie Helena Eickmann
Journal:  Dev Neurorehabil       Date:  2017-05-24       Impact factor: 2.308

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.